logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Liquid Biopsy Market, By Type (Blood Sample Based, Urine Sample Based, Others), By Application (Therapy Selection for Metastatic Breast Cancer (MBS), Molecular Health Monitoring, Therapy Selection for Other Metastatic Cancer,) opportunities and forecast 2020-2027

  • DLR2125
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Liquid biopsy is fast emerging ancillary method for the conventional tumor biopsies, established out of need to acquire most amount of molecular data about cancer with least amount of the surgical invasion. With rapid improvements in NGS technology, the liquid biopsies are projected to take key position in context of cancer related investigation and probe.

Furthermore, with expected positive results from number of clinical trials for development of these tests and following higher scaled clinical trials representative efficacy, it is expected that the testing procedure will serve broader base of patient in the molecular monitoring settings. The three most potential biofluids under enormous clinical observations for the liquid biopsy selection are urine, blood, and saliva.

Moreover, based on the form biopsy is probe into the free flowing circulating tumour cells, biomarkers utmost suited and being studied for feasible commercial development inlcude circulating tumor DNA, CTCs, and exosomes containing tumor RNA or DNA. Technologies under the R&D include the PCR-based assays for the single gene analysis and the NGS-based parallel gene analysis.

Segment Overview

Implications of the complete commercialization of various liquid biopsies procedure is expected to be greatly disruptive. Three key uses of liquid biopsy can be as the therapy selection tool for the metastatic breast cancers, and for other metastatic cancers, as well as molecular health monitoring. With the growing incidence of metastatic cancer around the world, therapy selection tool for the metastatic breast cancers segment is expected to hold a substantial share in market throughout the projection period.

Once a considerable number of the liquid biopsy products are commercialized, the liquid biopsy is expected to find application not only in the cancer diagnosis, but as molecular monitoring diagnostic tool for various other diseases, that can be investigated using various biofluids such as CSF, blood, urine and saliva for the cancer recurrences, patient screening, and other associated prognosis.

Regional Overview

The market for liquid biopies has been on rise in most of regions owing to the growing incidence of cancer and consequently rising need for the screening and growing competition between various biotechnology firms to enter the untapped markets around the globe. Besides these, the government grants for the research institutes to revolutionise and improve the available liquid biopsy testing approaches are expected to back the growth of market.
North America was expecting to command the major market share in 2019, followed by the Europe. The growth in the region can be accredited to the recent regulatory sanctions by CE for the commercial use of the liquid biopsy tests. On the other hand, Asia Pacific is expected to register remarkable CAGR over the forecast period as the governments and market players are trying to keep rising cancer prevalence rates in region in check. India, China, and Japan are the foremost contributing countries to the growth in the region.

Competitor overview

Some of the vital players that have commercialized their tests in liquid biopsy are Biocept, Guardant Health, Trovagene, Personal Genome Diagnostics, Cynvenio, NeoGenomics Laboratories, Adaptive Biotechnologies, Qiagen, and RainDance Technologies.
Many biotech companies have started trials in China as the clinical trial regulations are reasonably lenient. Thus, inspiring the companies to shift their base from North America and Europe, where pricier trials are required for the approval and reimbursement.

Key Players
  1. Guardant Health,
  2. Personal Genome Diagnostics
  3. Biocept
  4. Adaptive Biotechnologies
  5. Cynvenio, NeoGenomics Laboratories
  6. Qiagen
  7. Trovagene
  8. RainDance Technologies

Market Segmentation

By Type
  • Blood Sample-based
  • Urine Sample-based
  • Other Bio Fluids (Tissue fluids and Saliva) based
By Application
  • Therapy Selection for Metastatic Breast Cancer (MBS)
  • Therapy Selection for Other Metastatic Cancer
  • Molecular Health Monitoring
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 15

    2 Introduction 16

    • 2.1 Scope of Study 16
    • 2.2 Research Objective 16
    • 2.3 Assumptions & Limitations 17
      • 2.3.1 Assumptions 17
      • 2.3.2 Limitations 17
    • 2.4 Market Structure 17

    3 Research Methodology 18

    • 3.1 Research Process 18
    • 3.2 Primary Research 19
    • 3.3 Secondary Research 19

    4 Market Dynamics 20

    • 4.1 Introduction 20
    • 4.2 Drivers 20
      • 4.2.1 Comparatively painless and non-invasive technique 20
      • 4.2.2 Early real time high precision detection of diseases 20
      • 4.2.3 Useful for designing effective treatment strategies based on the real time molecular assessment for the progression of the disease 21
      • 4.2.4 Rise in cases of cancer and other diseases 21
      • 4.2.5 Lifestyle changes and environmental factors 21
      • 4.2.6 Other advantages over other techniques 22
      • 4.2.7 The recent technological advancements has increased the appeal of liquid biopsy 22
      • 4.2.8 Transferability of liquid biopsy 22
      • 4.2.9 Rising investment in research and development and collaborations between companies and public organizations 23
      • 4.2.10 Greater focus on venture capital 23
      • 4.2.11 Demographical factors 23
    • 4.3 Restraints 24
      • 4.3.1 Prohibitive costs associated with liquid biopsy 24
      • 4.3.2 Lower sensitivity for certain biomarkers 24
      • 4.3.3 Not all cancers patients benefit from early detection 24
      • 4.3.4 Liquid biopsy is not all non-invasive 24
      • 4.3.5 Differential awareness and availability between developing and developed world 25
      • 4.3.6 Issues in venture capital, startups and collaborations 25
    • 4.4 Opportunities 25
      • 4.4.1 Growing collaboration between companies has become the entrance gateway for new firms 25
      • 4.4.2 Funding from public organizations is a good strategy to reduce development costs 26
      • 4.4.3 Rise in research and development investment 26
      • 4.4.4 Developing economies provide an unserved market for liquid biopsy 26
      • 4.4.5 Growing trend of start-ups and venture investment in the field of liquid biopsy 26
    • 4.5 Challenges 27
      • 4.5.1 Information and interest gap between the investors and the developers 27
      • 4.5.2 Lack of trained professionals in developing regions 27
      • 4.5.3 Lack of standardization and transparency 27

    5 Market Factor Analysis 28

    • 5.1 Porter’s Five Force Analysis 28
      • 5.1.1 Bargaining Power of Buyer 29
      • 5.1.2 Bargaining Power of Supplier 30
      • 5.1.3 Threat from substitute 30
      • 5.1.4 Threat from a New Entrant 30
      • 5.1.5 Intensity of Competitive Rivalry 31
    • 5.2 Value Chain Analysis 32
      • 5.2.1 Device Manufacturers 32
      • 5.2.2 Software developers 32
      • 5.2.3 Reagent and accessory suppliers 32
      • 5.2.4 Healthcare providers 32
      • 5.2.5 Patients 32

    6 Liquid Biopsy Market, By Biomarker Types 33

    • 6.1 Introduction 34
    • 6.2 Circulating Tumor Cells (CTCs) 36
    • 6.3 Circulating Tumour DNA (CtDNA) 37
    • 6.4 Extracellular Vesicles (EVs) 39
    • 6.5 Other biomarker (circulating RNA and proteins) 40

    7 Global Liquid Biopsy Market, By Application 41

    • 7.1 Introduction 41
    • 7.2 Cancer 43
    • 7.3 Reproductive health 44
    • 7.4 Other therapeutic application 45

    8 Global Liquid Biopsy Market, By Sample 47

    • 8.1 Introduction 47
    • 8.2 Blood Sample 49
    • 8.3 Urine sample 50
    • 8.4 Other sample 51

    9 Global Liquid Biopsy Market by End User 52

    • 9.1 Introduction 52
    • 9.2 Hospitals and Laboratories 54
    • 9.3 Academic and Research Centres 55
    • 9.4 Other end users 56

    10 Global liquid Biopsy Market, by Region 57

    • 10.1 Introduction 57
    • 10.2 North America 59
      • 10.2.1 US
      • 10.2.2 CANADA 68
    • 10.3 Europe 72
      • 10.3.1 Germany 77
      • 10.3.2 France 81
      • 10.3.3 U.K. 85
      • 10.3.4 Italy 89
      • 10.3.5 Spain 93
      • 10.3.6 Rest of Europe 97
    • 10.4 Asia-Pacific 102
      • 10.4.1 Japan 107
      • 10.4.2 China 111
      • 10.4.3 India 115
      • 10.4.4 Australia 119
      • 10.4.5 Korea 123
      • 10.4.6 Rest of Asia Pacific 127
    • 10.5 Middle East and Africa 132
      • 10.5.1 UAE 137
      • 10.5.2 Saudi Arabia 141
      • 10.5.3 Egypt 145
      • 10.5.4 Rest of Middle East and Africa 149

    11 Company Profile 154

    • 11.1 Guardant Health, Inc 154
      • 11.1.1 Company Overview 154
      • 11.1.2 Product/Business Segment Overview 154
      • 11.1.3 Financial Overview 154
      • 11.1.4 Key Development 155
      • 11.1.5 SWOT Analysis 156
    • 11.2 Trovagene, Inc 157
      • 11.2.1 Company Overview 157
      • 11.2.2 Product/Business Segment Overview 157
      • 11.2.3 Financial Overview 157
      • 11.2.4 SWOT Analysis 158
    • 11.3 RainDance Technologies, Inc. 159
      • 11.3.1 Company Overview 159
      • 11.3.2 Product/Business Segment Overview 159
      • 11.3.3 Financial Overview 159
      • 11.3.4 Key Development 160
      • 11.3.5 SWOT Analysis 160
    • 11.4 Agena Bioscience Inc. Inc. 161
      • 11.4.1 Company Overview 161
      • 11.4.2 Product/Business Segment Overview 161
      • 11.4.3 Financial Overview 161
      • 11.4.4 Key Development 161
      • 11.4.5 SWOT Analysis 162
    • 11.5 Admera Health 163
      • 11.5.1 Company Overview 163
      • 11.5.2 Product/Business Segment Overview 163
      • 11.5.3 Financial Overview 163
      • 11.5.4 Key Development 163
      • 11.5.5 SWOT Analysis 164
    • 11.6 Biocept, Inc. 165
      • 11.6.1 Company Overview 165
      • 11.6.2 Product/Business Segment Overview 165
      • 11.6.3 Financial Overview 165
      • 11.6.4 Key Development 165
    • 11.7 Circulogene Theranostics 166
      • 11.7.1 Company Overview 166
      • 11.7.2 Product/Business Segment Overview 166
      • 11.7.3 Financial Overview 166
      • 11.7.4 Key Development 166
    • 11.8 Inivata Ltd 167
      • 11.8.1 Company Overview 167
      • 11.8.2 Product/Business Segment Overview 167
      • 11.8.3 Financial Overview 167
      • 11.8.4 Key Development 167
    • 11.9 SAGA Diagnostics AB 168
      • 11.9.1 Company Overview 168
      • 11.9.2 Product/Business Segment Overview 168
      • 11.9.3 Financial Overview 168
      • 11.9.4 Key Development 168
    • 11.10 Exosome Diagnostics 169
      • 11.10.1 Company Overview 169
      • 11.10.2 Product/Business Segment Overview 169
      • 11.10.3 Financial Overview 169

    Report You Might be Interested